Antipsychotics (Neuroleptics)

  • Magda Campbell
  • Nilda M. Gonzalez
  • Monique Ernst
  • Raul R. Silva
  • John S. Werry


Antipsychotic drugs are a large group of psychoactive agents mainly known for their antipsychotic clinical properties, though they are also effective in a variety of nonpsychotic disorders. Formerly, these drugs were called neuroleptics, because of their special sedative property.1


Antipsychotic Drug Tardive Dyskinesia Autistic Child Tourette Syndrome Neuroleptic Malignant Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Delay J, Deniker P: 38 cas de psychoses traitées par la cure prolongée et continue de 4560 RP-CR. 50iéme Congres des Alien et Neurologique de Langue Francaise, Luxembourg, 21-27 July, 1952, p 503.Google Scholar
  2. 2.
    Davis JM, Barter JT, Kane JM: Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds): Comprehensive Textbook of Psychiatry, ed 5. Baltimore, Williams & Wilkins, 1989, vol II, pp 1591–1621.Google Scholar
  3. 3.
    Deutsch SI, Campbell M: Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism: A hypothesis. Neuropsychobiology 15: 160–164, 1986.PubMedGoogle Scholar
  4. 4.
    Davis KL, Kahn RS, Ko G, et al: Dopamine in schizophrenia. A review and reconceptualization. Am J Psychiatry 148: 1474–1486, 1991.PubMedGoogle Scholar
  5. 5.
    Sokoloff P, Giros B, Martres MP, et al: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–159, 1990.PubMedGoogle Scholar
  6. 6.
    Gould RJ, Murphy KMM, Reynolds IJ, et al: Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 80: 5122–5125, 1983.PubMedGoogle Scholar
  7. 7.
    Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522, 1980.PubMedGoogle Scholar
  8. 8.
    Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336, 1984.PubMedGoogle Scholar
  9. 9.
    Ernst M, Magee HJ, Gonzalez NM, et al: Pimozide in autistic children. Psychopharmacol Bull 28: 187–191, 1992.PubMedGoogle Scholar
  10. 10.
    Geller B: Psychopharmacology of children and adolescents: Pharmacokinetics and relationships of plasma/serum levels to response. Psychopharmacol Bull 27(4): 401–409, 1991.PubMedGoogle Scholar
  11. 11.
    Furlanut M, Benetello P, Baraldo M, et al: Chlorpromazine disposition in relation to age in children. Clin Pharmacokinet 18: 329–331, 1990.PubMedGoogle Scholar
  12. 12.
    Morselli PL, Bianchetti G, Durand G, et al: Haloperidol plasma level monitoring in pediatric patients. Ther Drug Monitor 1: 35–46, 1979.Google Scholar
  13. 13.
    Poland RE, Campbell M, Rubin RT, et al: Relationship of serum haloperidol levels and clinical response in autistic children. Paper presented at the 13th CINP Congress (Collegium Internationale Psychopharmacologicum), Jerusalem, June 20-25, 1982.Google Scholar
  14. 14.
    Rivera-Calimlin L, Griesbach PH, Perlmutter R: Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness. Clin Pharmacol Ther 26: 114–121, 1979.Google Scholar
  15. 15.
    Campbell M, Poland RE, Perry R, et al: Serum haloperidol levels and prolactin levels and clinical response in autistic children. Paper presented at the 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry with the Canadian Academy of Child Psychiatry, Seattle, October 27, 1988.Google Scholar
  16. 16.
    Gittelman-Klein R, Klein DF, Katz S, et al: Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. Arch Gen Psychiatry 33: 1217–1231, 1976.PubMedGoogle Scholar
  17. 17.
    Rivera-Calimlin L, Nasrallah H, Strauss J, et al: Clinical response and plasma levels: Effect of dose, dosage, schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133: 646–652, 1976.Google Scholar
  18. 18.
    Geller B, Cooper TB, Farooki ZQ, et al: Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents. Am J Psychiatry 142: 336–338, 1985.PubMedGoogle Scholar
  19. 19.
    Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev (DSM-III-R). Washington, DC, American Psychiatric Association Press, 1987.Google Scholar
  20. 20.
    Diagnostic and Statistical Manual of Mental Disorders, ed 3 (DSM-III). Washington, DC, American Psychiatric Association Press, 1980.Google Scholar
  21. 21.
    International Classification of Diseases ICD-9. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Geneva, World Health Organization, 1977, vol 1.Google Scholar
  22. 22.
    Thompson JW, Green D, Savit HL: Preliminary report on a crosswalk from DSM-III to ICD-9-CM. Am J Psychiatry 140: 176–180, 1983.PubMedGoogle Scholar
  23. 23.
    Physicians Desk Reference, ed 46. Oradell, NJ, Medical Economics, 1992.Google Scholar
  24. 24.
    Simpson GM: Pharmacology and treatment of the major psychoses. Paper presented at the 30th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 9-13, 1991.Google Scholar
  25. 25.
    Abnormal Involuntary Movements Scale. Psychopharmacol Bull 21(4): 1077–1080, 1985.Google Scholar
  26. 26.
    Campbell M: Protocol for rating drug-related AIMS, stereotypies and CPRS assessments. Psychopharmacol Bull Spec Feature 21(4): 1081, 1985.Google Scholar
  27. 27.
    Campbell M, Palij M: Measurement of untoward effects including tardive dyskinesia. Psychopharmacol Bull 21(4): 1063–1082, 1985.PubMedGoogle Scholar
  28. 28.
    Campbell M, Spencer EK, Kowalik SC, et al: Schizophrenic and psychotic disorders, in Wiener JM (ed): Textbook of Child and Adolescent Psychiatry. Washington, DC, American Psychiatric Association Press, 1991, pp 223–239.Google Scholar
  29. 29.
    Spencer EK, Kafantaris V, Padron-Gayol M, et al: Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull, 28(2): 183–186, 1992.PubMedGoogle Scholar
  30. 30.
    Pool D, Bloom W, Mielke DH, et al: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic adolescents. Curr Ther Res 19: 99–104, 1976.PubMedGoogle Scholar
  31. 31.
    Realmuto GM, Ekickson WD, Yellin A, et al: Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141: 440–442, 1984.PubMedGoogle Scholar
  32. 32.
    Kane J, Honigfeld G, Singfer J, et al: Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 45: 789–796, 1988.PubMedGoogle Scholar
  33. 33.
    Siefen G, Remschmidt H: Behandlungsergebnisse mit clozapin bei schizophrenen Jugendlichen. Z Kinder-Jugendpsychiat 14: 245–257, 1986.Google Scholar
  34. 34.
    Birmaher B, Baker R, Kapur S, et al: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 31: 160–164, 1992.PubMedGoogle Scholar
  35. 35.
    McClellan JM, Werry JS: Schizophrenia, in Shaffer D (ed): The Psychiatric Clinics of North America. Philadelphia, WB Saunders 1992, vol 15, pp 131–148.Google Scholar
  36. 36.
    Werry JS, McClellan JM, Chard L: Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: A clinical and outcome study, J Am Acad Child Adolesc Psychiatry 30: 457–465, 1991.PubMedGoogle Scholar
  37. 37.
    Goodwin FK, Jamison KR: Manic-Depressive Illness. London, Oxford University Press, 1990.Google Scholar
  38. 38.
    Loranger AW, Levine PM: Age at onset of bipolar affective illness. Arch Gen Psychiatry 35: 1345–1348, 1978.PubMedGoogle Scholar
  39. 39.
    Carlson GA: Child and adolescent mania: Diagnostic considerations. J Child Psychol Psychiatry 31: 331–341, 1990.PubMedGoogle Scholar
  40. 40.
    Shopsin B, Gershon S, Thompson H, et al: Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 32: 34–42, 1975.PubMedGoogle Scholar
  41. 41.
    Campbell M, Gonzalez NM, Silva RR: The pharmacologic treatment of conduct disorders and rage outbursts, in Shaffer D (ed): The Psychiatric Clinics of North America. Philadelphia, WB Saunders, 1992, vol 15, pp 69–85.Google Scholar
  42. 42.
    Cunningham MA, Pillai V, Rogers WJB: Haloperidol in the treatment of children with severe behavioural disorders. Br J Psychiatry 114: 845–854, 1968.PubMedGoogle Scholar
  43. 43.
    Werry JS, Aman MG, Lampen E: Haloperidol and methylphenidate in hyperactive children. Acta Paedopsychiatr 42: 26–40, 1975.Google Scholar
  44. 44.
    Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41: 650–656, 1984.PubMedGoogle Scholar
  45. 45.
    Greenhill LL, Barmack JE, Spalten D, et al: Molindone hydrochloride in the treatment of aggressive, hospitalized children. Psychopharmacol Bull 17: 125–127, 1981.PubMedGoogle Scholar
  46. 46.
    Greenhill LL, Solomon M, Pleak R, et al: Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 46: 20–25, 1985.PubMedGoogle Scholar
  47. 47.
    Children’s Psychiatric Rating Scale (CPRS). Psychopharmacol Bull 21(4): 765–770, 1985.Google Scholar
  48. 48.
    Wong GH, Cock RJ: Long-term effects of haloperidol on severely emotionally disturbed children. Aust NZ J Psychiatry 5: 296–300, 1971.Google Scholar
  49. 49.
    Werry JS, Aman MG: Methylphenidate and haloperidol in children: Effects on attention, memory and activity. Arch Gen Psychiatry 32: 790–795, 1975.PubMedGoogle Scholar
  50. 50.
    Platt JE, Campbell M, Green WH, et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41: 657–662, 1984.PubMedGoogle Scholar
  51. 51.
    Fish B, Shapiro T, Campbell M: Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry 123: 32–39, 1966.PubMedGoogle Scholar
  52. 52.
    Campbell M, Anderson LT, Meier M, et al: A comparison of haloperidol, behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17: 640–655, 1978.PubMedGoogle Scholar
  53. 53.
    Anderson LT, Campbell M, Grega DM, et al: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141: 1195–1202, 1984.PubMedGoogle Scholar
  54. 54.
    Anderson LT, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19: 227–239, 1989.PubMedGoogle Scholar
  55. 55.
    Naruse H, Nagahata M, Nakane Y, et al: A multicenter double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 48: 173–184, 1982.PubMedGoogle Scholar
  56. 56.
    Cohen IL, Campbell M, Posner D, et al: Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19: 665–677, 1980.PubMedGoogle Scholar
  57. 57.
    Campbell M: Pharmacotherapy in early infantile autism. Biol Psychiatry 10: 399–423, 1975.PubMedGoogle Scholar
  58. 58.
    Campbell M, Schopler E (co-chairpersons): Pervasive developmental disorders, in: Karasu TB (chairperson): Treatments of Psychiatric Disorders: A Task Force Report. Washington DC, American Psychiatric Association Press, 1989, vol 1, pp 179–294.Google Scholar
  59. 59.
    Tarjan C, Lowery VE, Wright SW: Use of chlorpromazine in two hundred seventy-eight mentally deficient patients. AMA J Disturbed Child 94: 294–300, 1957.Google Scholar
  60. 60.
    Pregelj S, Barkauskas A: Thioridazine in the treatment of mentally retarded children. A four-year retroactive evaluation. J Can Psychiatr Assoc 12: 213–215, 1967.Google Scholar
  61. 61.
    Freeman RD: Psychopharmacology and the retarded child, in Menolascino F (ed): Psychiatric Approaches to Mental Retardation. New York, Basic Books, 1970, pp 294–368.Google Scholar
  62. 62.
    Campbell M, Fish B, Shapiro T, et al: Thiothixene in young disturbed children: A pilot study. Arch Gen Psychiatry 23: 70–72, 1970.PubMedGoogle Scholar
  63. 63.
    Campbell M, Fish B, Shapiro T, et al: Study of molindone in disturbed preschool children. Curr Ther Res 13: 28–33, 1971.PubMedGoogle Scholar
  64. 64.
    Locascio JJ, Malone RP, Small AS, et al: Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27(2): 119–126, 1991.PubMedGoogle Scholar
  65. 65.
    Rett A: Über ein eingenartiges hirntrophisches Syndrome bei Hyperammonamie in Kindersalter. Wien Med Wochenschr 166: 723–738, 1966.Google Scholar
  66. 66.
    Perry R, Campbell M, Adams P, et al: Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28: 87–92, 1989.PubMedGoogle Scholar
  67. 67.
    Die Trill ML, Wolsky BB, Shell J, et al: Effects of long term haloperidol treatment on intellectual functioning in autistic children: A pilot study. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, Toronto, October 10–14, 1984.Google Scholar
  68. 68.
    Shell J, Perry R, Adams P, et al: Effects of long-term haloperidol treatment on intellectual functioning in autistic children. Paper presented at the 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 21–25, 1987.Google Scholar
  69. 69.
    Borison RL, Ang L, Chang S, et al: New pharmacological approaches in the treatment of Tourette syndrome, in Friedhoff AJ, Chase TN (eds): Gilles de la Tourette Syndrome. New York, Raven Press, 1982, pp 377–382.Google Scholar
  70. 70.
    Shapiro E, Shapiro AK, Fulop G, et al: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 46: 722–730, 1989.PubMedGoogle Scholar
  71. 71.
    Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s Disorder. Am J Psychiatry 145: 621–624, 1988.PubMedGoogle Scholar
  72. 72.
    Campbell M, Malone RP: Mental retardation and psychiatry disorders. Hosp Community Psychiatry 42: 374–379, 1991.PubMedGoogle Scholar
  73. 73.
    Aman MG, Singh NN: Psychopharmacology of the Developmental Disabilities. Berlin, Springer-Verlag, 1988, pp 1–28.Google Scholar
  74. 74.
    Gadow KD, Poling AG: Pharmacotherapy and Mental Retardation. Boston, College-Hill Press, 1988.Google Scholar
  75. 75.
    Aman MG, Singh NN: Pharmacological intervention, in Matson JL, Mulick JA (eds): Handbook of Mental Retardation, ed 2. New York, Pergamon Press, 1991, pp 347–372.Google Scholar
  76. 76.
    Intagliata J, Rimck C: Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacol Bull 21: 268–278, 1985.PubMedGoogle Scholar
  77. 77.
    Aman MG: Drugs and learning in mentally retarded persons, in Burrows GD, Werry JS (eds): Advances in Human Psychopharmacology. Greenwich, Conn, JAI Press, 1984, vol 3, pp 121–163.Google Scholar
  78. 78.
    Aman MG, White AJ, Field C: Chlorpromazine effects on stereotypic and conditioned behaviour of severely retarded patients — A pilot study. J Ment Defic Res 28: 253–260, 1984.PubMedGoogle Scholar
  79. 79.
    Aman MG, Marks RE, Turbott SH, et al: Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30(2): 246–256, 1991.PubMedGoogle Scholar
  80. 80.
    Singh NN, Aman MG: Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic 85: 580–587, 1981.PubMedGoogle Scholar
  81. 81.
    White AJ, Aman MG: Pimozide treatment in disruptive severely retarded patients. Aust NZ J Psychiatry 19: 92–94, 1985.Google Scholar
  82. 82.
    Aman MG, Teehan CJ, White AJ, et al: Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. Am J Ment Retard 95: 452–460, 1989.Google Scholar
  83. 83.
    Aman MG, White AJ: Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. J Autism Dev Disord 18: 355–366, 1988.PubMedGoogle Scholar
  84. 84.
    Claghorn JL: A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children. Curr Ther Res 14: 785–789, 1972.PubMedGoogle Scholar
  85. 85.
    Aman MG, Singh NN: Manual for the Aberrant Behavior Checklist. East Aurora, NY, Slosson Educational Publications, 1986.Google Scholar
  86. 86.
    Goldberg JB, Kurland AA: Pimozide in the treatment of behavioral disorders of hospitalized adolescents. J Clin Pharmacol 14: 134–139, 1974.PubMedGoogle Scholar
  87. 87.
    Aman MG, Marks RE, Turbott SH, et al: Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30: 816–824, 1991.PubMedGoogle Scholar
  88. 88.
    Sleator E, von Neumann A, Sprague R: Hyperactive children: A continuous long-term placebocontrolled follow-up. JAMA 229: 316–317, 1974.PubMedGoogle Scholar
  89. 89.
    Werry JS, Weiss G, Douglas V, et al: Studies on the hyperactive child: III. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry 5: 292–312, 1966.PubMedGoogle Scholar
  90. 90.
    Rapoport J, Abramson A, Alexander D, et al: Playroom observations on hyperactive children on medication. J Am Acad Child Psychiatry 10: 524–534, 1971.PubMedGoogle Scholar
  91. 91.
    Aman MG: Drugs, learning and the psychotherapies, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978.Google Scholar
  92. 92.
    Baldasserini R: Drugs and the treatment of psychiatric disorders, in Gilman A, Rall TW, Nies AS (eds): Goodman-Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Maxwell/ McMillan, 1991, pp 383–437.Google Scholar
  93. 93.
    Mikkelson EJ, Detlor J, Cohen DJ: School avoidance and social phobia triggered by haloperidol in patients with Tourette’s disorder. Am J Psychiatry 138: 1572–1575, 1981.Google Scholar
  94. 94.
    Richardson MA, Haugland G, Craig TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 148: 1322–1328, 1991.PubMedGoogle Scholar
  95. 95.
    Kane JM, Jeste DV, Barnes TRE, et al: Tardive Dyskinesia: A Task Force Report. Washington, DC, American Psychiatric Association Press, 1991.Google Scholar
  96. 96.
    Owens DGC, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 39: 452–461, 1982.PubMedGoogle Scholar
  97. 97.
    Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 30: 102–105, 1974.PubMedGoogle Scholar
  98. 98.
    Van Putten T, May PRA, Marder SR: Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41: 1036–1039, 1984.PubMedGoogle Scholar
  99. 99.
    Delay J, Deniker P: Drug-induced extrapyramidal syndromes, in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland Publishing Co, 1968, pp 248–266.Google Scholar
  100. 100.
    Rifkin A, Quitkin F, Klein DF: Akinesia. A poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32: 672–674, 1975.Google Scholar
  101. 101.
    Campbell M, Cohen IL, Small AM: Drugs in aggressive behavior. J Am Acad Child Psychiatry 21: 107–117, 1982.PubMedGoogle Scholar
  102. 102.
    Gardos G, Cole JO: Weight reduction in schizophrenia by molindone. Am J Psychiatry 134: 302–304, 1977.PubMedGoogle Scholar
  103. 103.
    Simpson GM: APA Task Force on Sudden Death. Washington, DC, American Psychiatric Association Press, 1987.Google Scholar
  104. 104.
    Pope HG, Keck PE, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143: 1227–1233, 1986.PubMedGoogle Scholar
  105. 105.
    Silver JM, Yudofsky SC: Psychopharmacology and electroconvulsive therapy, in Talbott JA, Hales RE, Yudofsky SC (eds): The American Psychiatric Press Textbook of Psychiatry. Washington, DC, American Psychiatric Press, 1989, pp 767–843.Google Scholar
  106. 106.
    Levinson F, Simpson GM: Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psychiatry 43: 839–848, 1986.PubMedGoogle Scholar
  107. 107.
    Geller B, Greydanus DE: Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: Two case reports with a literature review. J Clin Psychiatry 40: 102–103, 1979.PubMedGoogle Scholar
  108. 108.
    Moyes D: Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 45: 1163–1164, 1973.PubMedGoogle Scholar
  109. 109.
    Klein SK, Levinsohn MW, Blumer JL: Accidental chlorpromazine ingestion as a cause of neuroleptic malignant syndrome in children. J Pediatr 107(6): 970–973, 1985.PubMedGoogle Scholar
  110. 110.
    Campbell M, Green WH, Deutsch SI (eds): Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985.Google Scholar
  111. 111.
    Villeneuve A: The rabbit syndrome: A peculiar extrapyramidal reaction. Can J Psychiatry 17: 69–72, 1972.Google Scholar
  112. 112.
    Campbell M, Adams P, Perry R, et al: Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacol Bull 24(2): 251–255, 1988.PubMedGoogle Scholar
  113. 113.
    Campbell M, Grega DM, Green WH, et al: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6: 207–222, 1983.PubMedGoogle Scholar
  114. 114.
    Perry R, Nobler MS, Campbell M: Case report: Tourette-like symptoms associated with chronic neuroleptic therapy in an autistic child. J Am Acad Child Adolesc Psychiatry 28: 93–96, 1989.PubMedGoogle Scholar
  115. 115.
    Klawans HL, Nausieda PA, Goetz CC, et al: Tourette-like symptoms following chronic neuroleptic therapy, in Friedhoff AJ, Chase TN (eds): Advances in Neurology. New York, Raven Press, 1982.Google Scholar
  116. 116.
    Smith RE. Domino EF: Dystonic and dyskinetic reactions induced by H1 antihistaminic medication, in Fann WE, Smith RC, Davis JN, et al (eds): Tardive Dyskinesia: Research and Treatment. Jamaica, NY, Spectrum Publications, 1980, pp 325–332.Google Scholar
  117. 117.
    Thach BT, Chase TN, Bosman JF: Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Med 293: 486–487, 1975.PubMedGoogle Scholar
  118. 118.
    Chadwick D, Reynolds EG, Marsden CD: Anticonvulsant induced dyskinesias. J Neurol Neurosurg Psychiatry 39: 1210–1218, 1979.Google Scholar
  119. 119.
    Gardos G, Cole JO, La Brie R: The assessment of tardive dyskinesia. Arch Gen Psychiatry 34: 1206–1212, 1977.PubMedGoogle Scholar
  120. 120.
    Gerlach J: Pathophysiological mechanisms underlying tardive dyskinesia, in Casey D, Chase TN, Christensen DE, et al (eds): Dyskinesia — Research and Treatment (Psychopharmacology suppl 2). Berlin, Springer-Verlag, 1985, pp 99–103.Google Scholar
  121. 121.
    Kane JM, Smith JM: Tardive dyskinesia. Arch Gen Psychiatry 39: 473–481, 1982.PubMedGoogle Scholar
  122. 122.
    Crane GE, Naranjo ER: Motor disorders induced by neuroleptics. Arch Gen Psychiatry 24: 178–184, 1971.Google Scholar
  123. 123.
    Gardos G, Cole J, Tarsy D: Withdrawal symptoms associated with antipsychotic drugs. Am J Psychiatry 135: 1321–1324, 1978.PubMedGoogle Scholar
  124. 124.
    McAndrew JB, Case Q, Treffert DA: Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J Autism Child Schizophr 2: 75–91, 1972.PubMedGoogle Scholar
  125. 125.
    Gualtieri CT, Quade D, Hicks RE, et al: Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 141: 20–23, 1984.PubMedGoogle Scholar
  126. 126.
    Engelhardt DM, Polizios P: Adverse effects of pharmacotherapy in childhood psychosis, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978.Google Scholar
  127. 127.
    Meiselas KD, Spencer EK, Oberfield R, et al: Differentiation of stereotypies from neurolepticrelated dyskinesias in autistic children. J Clin Psychopharmacol 9: 207–209, 1989.PubMedGoogle Scholar
  128. 128.
    Owens DGC, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenic with and without treatment with neuroleptics. Arch Gen Psychiatry 39: 452–461, 1982.PubMedGoogle Scholar
  129. 129.
    Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia (Letter to the editor). Arch Gen Psychiatry 39: 486–487, 1982.PubMedGoogle Scholar
  130. 130.
    Campbell M, Locascio JJ, Choroco MC, et al: Stereotypies and tardive dyskinesia: Abnormal movements in autistic children. Psychopharmacol Bull 26(2): 260–266, 1990.PubMedGoogle Scholar
  131. 131.
    Malone RP, Ernst M, Godfrey KA, et al: Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol Bull 27(2): 113–117, 1991.PubMedGoogle Scholar
  132. 132.
    Crane GE: Neuroleptics and their long-term effects on the central nervous system, in DeVeaugh-Geiss J (ed): Tardive Dyskinesia and Related Involuntary Movement Disorders. Boston, John Wright Publishing Co, 1982, pp 71–84.Google Scholar
  133. 133.
    McLean P, Casey DE: Tardive dyskinesia in an adolescent. Am J Psychiatry 135: 969–971, 1978.PubMedGoogle Scholar
  134. 134.
    Green WH, Campbell M, Wolsky BB, et al: Effects of short and long term haloperidol administration on growth in young autistic children. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, Toronto, October 10-14, 1984.Google Scholar
  135. 135.
    Hamill PVV, Drizd TA, Johnson CL, et al: NCHS Growth Charts, 1976. Monthly Vital Statistics Report, Health Examination Survey Data, National Center for Health Statistics Publication (HRA)76-1120, 25(3): 1–22, 1976.Google Scholar
  136. 136.
    Spencer EK, Campbell M: Schizophrenic children: Diagnosis, phenomenology and pharmacotherapy. Schizophr Bull 19: 1993 (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Magda Campbell
    • 1
  • Nilda M. Gonzalez
    • 1
  • Monique Ernst
    • 1
  • Raul R. Silva
    • 1
  • John S. Werry
    • 2
  1. 1.Department of PsychiatryNew York University Medical CenterNew YorkUSA
  2. 2.Emeritus ProfessorUniversity of AucklandAucklandNew Zealand

Personalised recommendations